Actionable news
0
All posts from Actionable news
Actionable news in BCRX: BioCryst Pharmaceuticals, Inc.,

Major owner of BioCryst Pharmaceuticals just picked up 106,800 shares

Bros. Advisors Baker, a major owner of BioCryst Pharmaceuticals, recently acquired 106,800 shares of the company. The buys took place at prices ranging from $7.00 to $7.29 per share, on dates ranging from January 21 to January 22, 2016. Baker now owns 14,722,225 shares of the company. Baker operates out of New York, NY. Some additional info was provided as follows:

Common shares held directly by Felix J. Baker and for which Felix J. Baker has sole beneficial ownership. These shares were received in an in kind pro rata distribution from an affiliated investment fund in January 2015 without consideration. Common shares held directly by Julian C. Baker and for which Julian C. Baker has sole beneficial ownership. These shares were received in an in kind pro rata distribu tion from an affiliated investment fund in January 2015 without consideration. As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Biotech Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 2,122,127 shares of Common Stock of BioCryst Pharmaceuticals, Inc. (the "Issuer") directly held by 667, L.P. ("667"), a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. The price in Column 4 is a weighted average price. These shares were traded in multiple transactions at prices ranging from $7.09 to $7.50, inclusive. The reporting persons undertake to provide to the Issuer, any security holder...

More